Inhibition of platelet activation by MM-706, a stable carbacyclin analog, in the conscious rat

General Pharmacology

Volumn 28, Issue 2, 1997, Pages 251-255

  Meggiato, C ^a   Padoin, E ^a   Ragazzi, E ^a   Chinellato, A ^a   Doni, M G ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

ADP; carbacyclin; MM 706; platelet; rat

Indexed keywords

ADENOSINE DIPHOSPHATE; CARBACYCLIN DERIVATIVE; ILOPROST; MM 706; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BOLUS INJECTION; CONSCIOUSNESS; CONTROLLED STUDY; DRUG ANTAGONISM; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD PRESSURE; EPOPROSTENOL; HEART RATE; ILOPROST; MALE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RATS; RATS, WISTAR;

EID: 0031021591     PISSN: 03063623     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-3623(96)00230-3     Document Type: Article

References (17)

1. Andersen N. H. (1988). Structure-activity correlation for prostanoid action. In: Prostaglandins: Biology and Chemistry of Prostaglandins and Related Eicosanoids. Edited by Curtis-Prior P. B., pp. 152-170. Churchill Livingstone, Edinburgh.
2. 1 with their effect on platelet aggregation and bleeding time in rats. Prostaglandins Leuk. Med. 10, 197-212.
3. Doni M. G. and Aragno R. (1975). ADP-induced platelet aggregation in vivo after exclusion of different circulatory districts. Experientia 31, 1224-1225.
4. Gorman R. R., Bunting S. and Miller O. V. (1977). Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13, 377-388.
5. Grant S. M. and Goa, K. L. (1992). Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 43, 889-924.
6. 2-mimetic, in rat and cynomolgus monkey. Prostaglandins 32, 425-438.
7. Kanger T., Lopp M., Müraus A., Löhmus M., Kobzar G., Pehk T. and Lille Ü. (1992). Synthesis of a novel, optically active 15-nonstereogenic carboprostacyclin. Synthesis N10, 925-927.
8. Kobzar G., Shelkovnikov S., Mardla V., Savitski G., Lopp M., Kanger T. and Lille Ü. (1994). A 15-nonstereogenic carbocyclin analogue of prostacyclin: effects on human platelets and uterine artery. J. Lipid Mediat. Cell Signal. 10, 243-249.
9. Kovacs I. B., Mayou S. C. and Kirby J. D. (1991). Infusion of a stable prostacyclin analogue, iloprost, to patients with peripheral vascular disease: lack of antiplatelet effect but risk of thromboembolism. Am. J. Med. 90, 41-46.
10. Lewis P. J. and Dollery C. T. (1983). Clinical pharmacology and potential of prostacyclin. Br. Med. Bull. 39, 281-284.
11. Lopp M., Bergmann M. and Lille Ü. (1989). Synthesis and anti-aggregatory activity of a new 15-achiral carbacyclin. Proc. Acad. Sci. ESSR Chem. 38, 58-59.
12. Lopp M., Kobzar G., Bergmann M., Pehk T., Lopp A., Välimäe T., Viigimaa M. and Lille Ü. (1992). Synthesis and antiaggregative activity of novel ω-achiral carba-analogues of prostacyclin. Eur. J. Med. Chem. 27, 155-159.
13. Moncada S., Gryglewski R. J., Bunting S. and Vane J. R. (1976). An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263, 663-665.
14. Ragazzi E., Chinellato A., Lille Ü., Lopp M., Doni M. G. and Fassina G. (1995). Pharmacological properties of MM-706, a new prostacyclin derivative. Gen. Pharmacol. 26, 703-709.
15. Radomski M. W., Rees D. D., Dutra A. and Moncada S. (1992). S-nitrosoglutathione inhibits activation in vitro and in vivo. Br. J. Pharmacol. 107, 745-749.
16. 2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications. J. Clin. Pharmacol. 28, 818-825.
17. Yamanishi J., Kawahara Y. and Fukuzaki H. (1983). Effect of cyclic AMP on cytoplasmic free calcium in human platelets stimulated by thrombin: direct measurement with quin 2. Thromb. Res. 32, 183-188.